[1] |
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui.
Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
|
[2] |
GUO Ningzi, LIU Li, YUE Ruiqi, FENG Huiqing, YANG Huaxin, WEI Ningyi, CHEN Hua.
Determination of particle size distribution of chiglitazar sodium by laser diffraction method
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 147-151.
|
[3] |
JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling.
Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
|
[4] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[5] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[6] |
ZHANG Jian, FANG Huihua.
Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189.
|
[7] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[8] |
XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue.
285 cases of adverse drug reaction related to new antineoplastic drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
|
[9] |
GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai.
One case of multiple organ dysfunction syndrome caused by amlodipine overdose
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
|
[10] |
FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan.
One case of generalized myalgia caused by oxaliplatin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
|
[11] |
CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin.
One case of interstitial pneumonia caused by serplulimab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
|
[12] |
CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili.
One case of severe liver injury caused by Tianma Shouwu tablets
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
|
[13] |
JIN Shengju, ZHOU Miao, ZHANG Jianing, GE Gonghui, ZHANG Tingjian, MENG Fanhao.
Research progress in novel xanthine oxidase inhibitors and treatment of gout
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 223-228.
|
[14] |
WANG Xin, SHI Leilei, ZHANG Yuhan, XIE Yundong, LIU Jiping.
The role of MRPs transporters in drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 229-234.
|
[15] |
GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe.
Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5.
|